An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) has appointed Dennis Cho as senior vice president, general counsel, and chief ethics and compliance officer. With over 25 years of corporate legal experience in the biotech industry, Cho aims to support Twist’s growth across synthetic biology and genomics. Previously, he held significant roles at CytomX Therapeutics and Seattle Genetics. CEO Emily Leproust expressed confidence in Cho's expertise to guide the company’s strategic initiatives. Twist strives to revolutionize DNA synthesis and applications across various industries, including healthcare and agriculture.
Positive
Dennis Cho brings over 25 years of legal experience, enhancing corporate governance.
His background in biotech will support strategic growth initiatives.
Cho's appointment is expected to strengthen Twist's compliance and transactional capabilities.
Negative
Concerns may arise regarding potential leadership continuity during transitions.
Experience gaps could affect immediate operational effectiveness.
SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Dennis Cho as senior vice president, general counsel and chief ethics and compliance officer. Mr. Cho brings more than 25 years of corporate legal experience, most of which has been in the biotech industry.
“Dennis is a giant of biopharma deals with a proven track record in, and commitment to, the biotech industry. He has provided counsel on all types of transactions and collaborations, which makes him ideal for the role at Twist,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We look forward to having his guidance as Twist continues to grow and expand.”
Mr. Cho was most recently assistant general counsel at CytomX Therapeutics, where he was department head for all deals and contracts as well as day-to-day lead on compliance and numerous other legal subject matters. Prior to CytomX, Mr. Cho was the lead transactional attorney on antibody-related licenses and collaborations, major commercial agreements, and combination trials at Seattle Genetics. Before that, he spent nine years at Celgene as the lead West Coast attorney supervising over 100 business transactions, including in- and out- licenses, options, collaborations and M&A agreements, and held primary legal responsibility for Celgene’s alliances, equity investments and “big data” machine learning initiative. Prior to Celgene, Mr. Cho served as general counsel for four private and public companies. He earned his J.D. and a B.A. in Molecular Cell Biology (Genetics) from University of California, Berkeley.
“I am thrilled to join the world class team at Twist. With four distinct areas of growth in synthetic biology, NGS, biopharma and data storage, the clear opportunity to really impact human progress by improving health and sustainability is both incredibly exciting and motivating,” said Mr. Cho.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
